GenVec Inc (GNVC) Rating Increased to Buy at Zacks Investment Research

GenVec Inc (GNVC) Rating Increased to Buy at Zacks Investment Research


The firm currently has a $0.50 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target indicates a potential upside of 2.02% from the company's previous close.



from Biotech News